HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

AbstractAIM:
This analysis investigates incidence and time course of rash in the EURTAC study.
MATERIALS & METHODS:
Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy.
RESULTS:
Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment.
CONCLUSION:
Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
AuthorsFilippo de Marinis, Alain Vergnenegre, Antonio Passaro, Catherine Dubos-Arvis, Enric Carcereny, Ana Drozdowskyj, Ali Zeaiter, Pablo Perez-Moreno, Rafael Rosell
JournalFuture oncology (London, England) (Future Oncol) Vol. 11 Issue 3 Pg. 421-9 ( 2015) ISSN: 1744-8301 [Electronic] England
PMID25675123 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (complications, drug therapy, genetics, mortality)
  • ErbB Receptors (genetics)
  • Erlotinib Hydrochloride
  • Exanthema (drug therapy, epidemiology, etiology, prevention & control)
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Lung Neoplasms (complications, drug therapy, genetics, mortality)
  • Mutation
  • Protein Kinase Inhibitors (administration & dosage, adverse effects)
  • Quinazolines (administration & dosage, adverse effects)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: